top of page
NEWS & EVENTS
Lario Therapeutics awarded $2.4m by The Michael J. Fox Foundation and Wellcome to expand neuronal calcium channel platform across CNS disorders
● New prestigious grants support Lario’s unique portfolio of calcium channel programmes ● Indication expansion into Parkinson’s disease, and PTSD (post-traumatic stress disorders) ● Builds on prior support from The Michael J. Fox Foundation and further validates Lario’s precision neuroscience platform Edinburgh, UK – 19 February 2026 – Lario Therapeutics (“Lario” or the “Company”), a biopharmaceutical company developing first-in-class precision medicines for epileptic and ne
Feb 19
Lario Therapeutics awarded $6M Grant from The Michael J. Fox Foundation for Parkinson’s Research
Award supports preclinical research of Lario’s CaV2.3 calcium channel inhibitors as a novel disease-modifying approach for treatment of...
Jul 22, 2024
Lario Therapeutics invited to present at the CACNA1E International Family Conference
Munich, Germany, 21 May 2024: Lario Therapeutics CEO Henning Steinhagen and CSO Tom Otis were invited to the inaugural CACNA1E Family...
May 31, 2024
Lario Therapeutics receives “Company Making a Difference Award” from CDLK5 Forum, recognising its unique approach to precision medicine for genetic epilepsies
“CDLK5 Forum Award for Excellence - Company Making a Difference 2023 Pre-clinical” presented by the Loulou Foundation at the CDKL5 Forum,...
Nov 7, 2023
bottom of page